[1]王睿健　张文超　尹　涛.CREPT在人脑胶质母细胞瘤组织中的表达及其与病人预后的关系[J].中国临床神经外科杂志,2021,26(01):20-22.[doi:10.13798/j.issn.1009-153X.2021.01.007]
　WANG Rui-jian,ZHANG Wen-chao,YIN Tao..Expression of CREPT in human glioblastoma tissues and its relationship with patients’ prognoses[J].,2021,26(01):20-22.[doi:10.13798/j.issn.1009-153X.2021.01.007]
点击复制

CREPT在人脑胶质母细胞瘤组织中的表达及其与病人预后的关系()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
26
期数:
2021年01期
页码:
20-22
栏目:
论著
出版日期:
2021-01-25

文章信息/Info

Title:
Expression of CREPT in human glioblastoma tissues and its relationship with patients’ prognoses
文章编号:
1009-153X（2021）01-0020-03
作者:
王睿健　张文超　尹　涛
053000 河北，衡水市人民医院神经外科（王睿健、张文超、尹　涛）
Author(s):
WANG Rui-jian;  ZHANG Wen-chao;  YIN Tao.
Department of Neurosurgery, People’s Hospital of Hengshui City, Hengshui 053000, China
关键词:
胶质母细胞瘤; 肿瘤高表达细胞周期相关蛋白; CREPT; 预后; 基因表达
Keywords:
Glioblastoma;  Cell cycle-related and expression elevated protein in tumor;  Prognosis
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2021.01.007
文献标志码:
A
摘要:
目的 探讨人脑胶质母细胞瘤（GBM）组织肿瘤高表达细胞周期相关蛋白（CREPT）的表达水平及其与病人预后的关系。方法 收集2010年1月至2011年1月手术切除的GBM组织104例和2018年1~12月颅脑损伤内减压术中切除的正常脑组织40例，采用免疫组织化学染色法检测CREPT的表达，根据染色情况将GBM分为高表达组和低表达组。GBM病人术后随访截止时间为2019年4月，记录总生存期（OS）和无进展生存期（PFS）。采用多因素Cox比例回归风险模型分析GBM病人生存预后的影响因素。用Kaplan-Meier法绘制生存曲线，采用Log-rank检验。结果 GBM组织CREPT高表达率（73.08%，76/104）明显高于正常脑组织（10.00%，4/40；P<0.05）。多因素Cox比例回归风险模型分析结果显示CREPT高表达是GBM病人OS和PFS较短的独立影响因素（P<0.05）。低表达组OS和PFS均明显高于高表达组（P<0.05）。结论 人脑GBM组织CREPT呈高表达，与病人不良生存预后和肿瘤进展有关。
Abstract:
Objective To investigate the expression of cell cycle-related and expression elevated protein in tumor (CREPT) in human glioblastoma (GBM) tissues and its relationship with patients’ prognoses. Methods The expressions of CREPT in GBM tissues obtained from 104 patients with GBM who underwent microsurgery from January 2010 to January 2011 and in normal cerebral tissues obtained from 40 patients with traumatic brain injury who underwent decompression were detected by immunohistochemistry. According to the staining, the level of CREPT expression were divided into high expression and low expression. The deadline for postoperative follow-up of GBM patients was April 2019, and overall survival (OS) and progression-free survival (PFS) were recorded. Results The high expression rate of CREPT in GBM tissues (73.08%, 76/104) was significantly higher than that (10.00%, 4/40) in normal brain tissues (P<0.05). Multivariate Cox proportional regression risk model analysis showed that high expression of CREPT was an independent risk factor for shorter OS and PFS in GBM patients (P<0.05). OS and PFS of GBM patients in the low expression group were significantly higher than those in the high expression group (P<0.05). Conclusion CREPT is highly expressed in human GBM tissues, which is related to the poor survival prognosis and tumor progression in GBM patients.

参考文献/References:

[1] 孙伟子，吴求吉，柳　麒，等. 胶质母细胞瘤治疗研究进展[J]. 中华实用诊断与治疗杂志，2019，33（10）：1037-1040.
[2] 夏靖华，张志培，文苗苗，等. CREPT和CDK4在非小细胞肺癌组织中的表达及临床意义[J]. 临床肿瘤学杂志，2018，23（4）：340-345.
[3] Zhang Y, Wang S, Kang W, et al. CREPT facilitates colorec-tal cancer growth through inducing Wnt/β-catenin pathway by enhancing p300-mediated β-catenin acetylation [J]. Oncogene, 2018, 37(26): 3485-3500.
[4] Wen N, Bian L, Gong J, et al. Overexpression of cell-cycle related and expression-elevated protein in tumor (CREPT) in malignant cervical cancer [J]. J Int Med Res, 2020, 48(1): 1-8.
[5] Yin H, Cao Q, Zhao H, et al. Expression of CREPT is asso-ciated with poor prognosis of patients with renal cell carci-noma [J]. Oncol Lett, 2019, 18(5): 4789-4797.
[6] Shi H, Zhang S. Expression and prognostic role of orphanreceptor GPR110 in glioma [J]. Biochem Biophys Res Commun, 2017, 491(2): 349-354.
[7] Lu D, Wu Y, Wang Y, et al. CREPT accelerates tumorigene-sis by regulating the transcription of cell-cycle-related genes [J]. Cancer Cell, 2012, 21(1): 92-104.（下转第25页）（上接第22页）
[8] 李晶晶，应杰儿. CREPT基因在肿瘤中的研究进展[J]. 临床与病理杂志，2016，36（9）：1436-1439.
[9] Sun M, Si G, Sun HS, et al. Inhibition of CREPT restrains gastric cancer growth by regulation of cycle arrest, migra-tion and apoptosis via ROS-regulated p53 pathway [J]. Biochem Biophys Res Commun, 2018, 496(4): 1183-1190.
[10] Liu H, Seynhaeve ALB, Brouwer RWW, et al. CREPT pro-motes melanoma progression through accelerated prolifera-tion and enhanced migration by RhoA-mediated actin filaments and focal adhesion formation [J]. Cancers (Basel), 2019, 12(1): 33-41.
[11] Liang Z, Feng Q, Xu L, et al. CREPT regulated by miR-138 promotes breast cancer progression [J]. Biochem Biophys Res Commun, 2017, 493(1): 263-269.
[12] Wei M, Cao Y, Jia D, et al. CREPT promotes glioma cellproliferation and invasion by activating Wnt/β-catenin pathway and is a novel target of microRNA-596 [J]. Biochimie, 2019, 162: 116-124.
[13] 马翔宇，李新钢，刘　佳，等. 影响胶质母细胞瘤切除术后的预后因素分析[J]. 中华神经外科杂志，2008，24（6）：464-467.

相似文献/References:

[1]谢宝树　张　林　王　宇　贾　锋　殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
　XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(01):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]宋贵东 综述　高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]
[3]李继强　杨吉安　邵灵敏　吴庭枫　刘宝辉　陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
　LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(01):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[4]桂志勇　冯　军　黄俊红　白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
　GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(01):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[5]王娇燕　孟凡华　刘魏然　魏春晓　林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
　WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[6]张治元　王汉东　樊友武　贾　玥　吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
　ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(01):69.
[7]郑锐哲　姜秀峰　陈二涛　孙兆良　冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[8]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
　HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(01):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[9]殷安安　陆　南　贺亚龙　章　翔　刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
　YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(01):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
[10]吴　蛟　易　勇　赵卓琳　周良学　周世军.贝伐珠单抗联合化疗治疗胶质母细胞瘤的meta分析[J].中国临床神经外科杂志,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]
　WU Jiao,YI Yong,ZHAO Zhuo-lin,et al.Efficacy and safety of bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis[J].,2020,(01):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]

备注/Memo

备注/Memo:
2020-05-21收稿
通讯作者：尹涛，E-mail：9168551@qq.com
更新日期/Last Update: 2021-01-25